MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute ...

Advocates for a Tennessee death row inmate are preparing their next legal steps after Gov. Lee granted Tony Von Carruthers a ...

MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today announced topline results ...

-- Peer-reviewed publication reports faster decongestion with Reprieve Therapy and no increased risk of safety events or worsening kidney function compared to optimal diuretic therapy -- MILFORD, Mass ...

Washington — Even with President Donald Trump granting an ambiguous one-month delay of blanket 25% tariffs on imported vehicles from Canada and Mexico, auto industry observers said Wednesday the ...

LOS ANGELES, March 12, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented findings from the REPRIEVE trial about the use of ...

Reprieve Cardiovascular Inc. landed $42 million in its first fundraising round out of stealth to fund development of its acute decompensated heart failure treatment. The series A round will support ...

-- Peer-reviewed publication reports faster decongestion with Reprieve Therapy and no increased risk of safety events or worsening kidney function compared to optimal diuretic therapy -- Reprieve ...

During the conference, Mr. Pacyna will discuss Reprieve’s recent corporate and clinical milestones, including the ongoing enrollment in the Company’s pivotal FASTR II clinical trial. The presentation ...

Reprieve Cardiovascular has closed an oversubscribed $61m Series B financing round, which was spearheaded by Deerfield Management. The funds aim to accelerate the global FASTR II pivotal trial of the ...